Corcept Therapeutics Incorporated (CORT)
$51.05
$-1.10
(-2.11%)
As on 07-May-2026 16:00EDT
Market cap
$5,598 Mln
Revenue (TTM)
$769 Mln
P/E Ratio
149
P/B Ratio
8.6
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
0.1 %
-
ROCE
-- %
-
Industry P/E
26.31
-
EV/EBITDA
99.1
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$0.4
-
Face value
--
-
Shares outstanding
107,356,686
10 Years Aggregate
CFO
$874.09 Mln
EBITDA
$719.20 Mln
Net Profit
$695.14 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Corcept Therapeutics (CORT)
| 46.7 | 25.0 | 33.1 | -27.8 | 28.5 | 18.6 | 26.7 |
|
BSE Sensex*
| -8.6 | 3.8 | -7.4 | -4.1 | 8.2 | 9.5 | 11.9 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Corcept Therapeutics (CORT)
| -30.9 | 54.6 | 59.9 | 2.6 | -24.3 | 116.2 | -9.4 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Corcept Therapeutics (CORT)
|
51.1 | 5,598.4 | 769.1 | 47.9 | 5.4 | 7.5 | 149 | 8.6 |
| 13.7 | 4,344.8 | 2,323.3 | 137.9 | 12.3 | -- | 61.9 | 105.4 | |
| 15.1 | 201.2 | 116.3 | -11.1 | -10.5 | -7.9 | -- | 1.5 | |
| 0.5 | 21.4 | 4.2 | -3.6 | -55.0 | -0 | -- | 0.9 | |
| 9.1 | 469.5 | 676.8 | -15.4 | 9.0 | -- | -- | 0.8 | |
| 3.1 | 1,150.8 | 839.3 | -57.5 | -2.3 | -7.1 | -- | 1.4 | |
| 8.1 | 5,723.6 | 7,682.7 | 438.7 | 15.9 | 7.5 | 12.2 | 0.9 | |
| 0.1 | 107.0 | 0.0 | -17.4 | -- | -- | -- | 14.4 | |
| 26.7 | 1,420.7 | 61.4 | -166.2 | -267.6 | -- | -- | 49.0 | |
| 23.6 | 932.2 | 734.9 | 9.3 | 2.6 | 1.3 | 182.2 | 1.5 |
Shareholding Pattern
View DetailsAbout Corcept Therapeutics (CORT)
Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. The company offers Korlym, an... oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. It also develops relacorilant, a selective cortisol modulator for patients with hypercortisolism; a selective cortisol modulator miricorilant, which is in Phase 1b trial for metabolic dysfunction-associated steatohepatitis; and a portfolio of proprietary selective cortisol modulators, such as relacorilant, nenocorilant, miricorilant, and dazucorilant for the treatment of Lou Gehrig's disease. The company was incorporated in 1998 and is headquartered in Redwood City, California. Address: 101 Redwood Shores Parkway, Redwood City, CA, United States, 94065 Read more
-
Co-Founder, President, CEO & Director
Dr. Joseph K. Belanoff M.D.
-
Co-Founder, President, CEO & Director
Dr. Joseph K. Belanoff M.D.
-
Headquarters
Redwood City, CA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Corcept Therapeutics (CORT)
What is the current share price of Corcept Therapeutics Incorporated (CORT) Today?
The share price of Corcept Therapeutics Incorporated (CORT) is $51.05 (NASDAQ) as of 07-May-2026 16:00 EDT. Corcept Therapeutics Incorporated (CORT) has given a return of 28.48% in the last 3 years.
What is the current PB & PE ratio of Corcept Therapeutics Incorporated (CORT)?
The P/E ratio of Corcept Therapeutics Incorporated (CORT) is 149.00 times as on 07-May-2026, a 466 premium to its peers’ median range of 26.31 times.
The P/B ratio of Corcept Therapeutics Incorporated (CORT) is 8.64 times as on 07-May-2026, a 48 premium to its peers’ median range of 5.84 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
41.86
|
6.44
|
|
2024
|
42.72
|
8.78
|
|
2023
|
33.93
|
7.11
|
|
2022
|
23.30
|
4.71
|
|
2021
|
21.55
|
6.45
|
What is the 52 Week High and Low of Corcept Therapeutics Incorporated (CORT)?
The 52-week high and low of Corcept Therapeutics Incorporated (CORT) are Rs 91.00 and Rs 28.66 as of 08-May-2026.
What is the market cap of Corcept Therapeutics Incorporated (CORT)?
Corcept Therapeutics Incorporated (CORT) has a market capitalisation of $ 5,598 Mln as on 07-May-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Corcept Therapeutics Incorporated (CORT)?
Before investing in Corcept Therapeutics Incorporated (CORT), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.